{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:06:32Z","timestamp":1771232792899,"version":"3.50.1"},"reference-count":42,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2023.0143","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T09:08:10Z","timestamp":1701248890000},"source":"Crossref","is-referenced-by-count":3,"title":["Testicular tumors"],"prefix":"10.3238","author":[{"given":"Susanne","family":"Krege","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Oing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"10.3238\/arztebl.m2023.0143_ref1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, et al.: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–49.","DOI":"10.3322\/caac.21660"},{"key":"10.3238\/arztebl.m2023.0143_ref2","doi-asserted-by":"crossref","unstructured":"Moch H, Amin MB, Berney DM, et al.: The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 2022; 82: 458–68.","DOI":"10.1016\/j.eururo.2022.06.016"},{"key":"10.3238\/arztebl.m2023.0143_ref3","doi-asserted-by":"crossref","unstructured":"Oosterhuis JW, Looijenga LHJ: Human germ cell tumours from a developmental perspective. Nat Rev Cancer 2019; 19: 522–37.","DOI":"10.1038\/s41568-019-0178-9"},{"key":"10.3238\/arztebl.m2023.0143_ref4","unstructured":"Dieckmann KP, Radtke A, Geczi L, et al.: Serum levels of microRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol 2019; 37: 1412–23."},{"key":"10.3238\/arztebl.m2023.0143_ref5","doi-asserted-by":"crossref","unstructured":"M\u00f8ller H, Skakkeb\u00e6k NE: Risk of testicular cancer in subfertile men: case-control study. BMJ 1999; 318: 559–62.","DOI":"10.1136\/bmj.318.7183.559"},{"key":"10.3238\/arztebl.m2023.0143_ref6","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens. Langversion 1.1. 2020. www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Hodentumoren\/LL_Hodentumoren_Langversion_1.1.pdf (last accessed on 23 December 2022)."},{"key":"10.3238\/arztebl.m2023.0143_ref7","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C, UICC: TNM classification of malignant tumours, 8 th edition due December 2016. Union for International Cancer Control 2017: 1–272."},{"key":"10.3238\/arztebl.m2023.0143_ref8","doi-asserted-by":"crossref","unstructured":"Mead GM: International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594–603.","DOI":"10.1200\/JCO.1997.15.2.594"},{"key":"10.3238\/arztebl.m2023.0143_ref9","doi-asserted-by":"crossref","unstructured":"Ruf CG, Schmidt S, Kliesch S, et al.: Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review. World J Urol 2022; 40: 2889–900.","DOI":"10.1007\/s00345-022-04145-6"},{"key":"10.3238\/arztebl.m2023.0143_ref10","doi-asserted-by":"crossref","unstructured":"Zengerling F, Kunath F, Jensen K, Ruf C, Schmidt S, Spek A: Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance—a systematic review. Urol Oncol 2018; 36: 448–58.","DOI":"10.1016\/j.urolonc.2017.06.047"},{"key":"10.3238\/arztebl.m2023.0143_ref11","doi-asserted-by":"crossref","unstructured":"Albers P, Siener R, Krege S, et al.: Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01\/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26: 2966–72.","DOI":"10.1200\/JCO.2007.12.0899"},{"key":"10.3238\/arztebl.m2023.0143_ref12","doi-asserted-by":"crossref","unstructured":"Oliver RTD, Mead GM, Rustin GJS, et al.: Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19\/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011; 29: 957–62.","DOI":"10.1200\/JCO.2009.26.4655"},{"key":"10.3238\/arztebl.m2023.0143_ref13","doi-asserted-by":"crossref","unstructured":"Donohue JP, Thornhill JA, Foster RS, Bihrle R, Rowland RG, Einhorn LH: The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 1995; 153: 85–9.","DOI":"10.1097\/00005392-199501000-00030"},{"key":"10.3238\/arztebl.m2023.0143_ref14","doi-asserted-by":"crossref","unstructured":"Papachristofilou A, Bedke J, Hayoz S, et al.: Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01\/10): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022; 23: 1441–50.","DOI":"10.1016\/S1470-2045(22)00564-2"},{"key":"10.3238\/arztebl.m2023.0143_ref15","doi-asserted-by":"crossref","unstructured":"Beyer J, Collette L, Sauv\u00e9 N, et al.: Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium. J Clin Oncol 2021; 39: 1553–62.","DOI":"10.1200\/JCO.20.03292"},{"key":"10.3238\/arztebl.m2023.0143_ref16","doi-asserted-by":"crossref","unstructured":"Gillessen S, Sauv\u00e9 N, Collette L, et al.: Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. J Clin Oncol 2021; 39: 1563–74.","DOI":"10.1200\/JCO.20.03296"},{"key":"10.3238\/arztebl.m2023.0143_ref17","doi-asserted-by":"crossref","unstructured":"Culine S, Kerbrat P, Kramar A, et al.: Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007; 18: 917–24.","DOI":"10.1093\/annonc\/mdm062"},{"key":"10.3238\/arztebl.m2023.0143_ref18","doi-asserted-by":"crossref","unstructured":"Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16: 1287–93.","DOI":"10.1200\/JCO.1998.16.4.1287"},{"key":"10.3238\/arztebl.m2023.0143_ref19","doi-asserted-by":"crossref","unstructured":"Daugaard G, Skoneczna I, Aass N, et al.: A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2011; 22: 1054–61.","DOI":"10.1093\/annonc\/mdq575"},{"key":"10.3238\/arztebl.m2023.0143_ref20","doi-asserted-by":"crossref","unstructured":"Bachner M, Loriot Y, Gross-goupil M, et al.: 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23: 59–64.","DOI":"10.1093\/annonc\/mdr052"},{"key":"10.3238\/arztebl.m2023.0143_ref21","doi-asserted-by":"crossref","unstructured":"Daneshmand S, Albers P, Foss\u00e5 SD, et al.: Contemporary management of postchemotherapy testis cancer. Eur Urol 2012; 62: 867–76.","DOI":"10.1016\/j.eururo.2012.08.014"},{"key":"10.3238\/arztebl.m2023.0143_ref22","doi-asserted-by":"crossref","unstructured":"Besse B, Grunenwald D, Fl\u00e9chon A, et al.: Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg 2009; 137: 448–52.","DOI":"10.1016\/j.jtcvs.2008.09.032"},{"key":"10.3238\/arztebl.m2023.0143_ref23","doi-asserted-by":"crossref","unstructured":"Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C: Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 1997; 33: 843–7.","DOI":"10.1016\/S0959-8049(96)00517-5"},{"key":"10.3238\/arztebl.m2023.0143_ref24","doi-asserted-by":"crossref","unstructured":"Lorch A, Beyer J, Kramar A, et al.: Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010; 28: 4906–11.","DOI":"10.1200\/JCO.2009.26.8128"},{"key":"10.3238\/arztebl.m2023.0143_ref25","doi-asserted-by":"crossref","unstructured":"Lorch A, Bascoul-Mollevi C, Kramar A, et al.: Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178–84.","DOI":"10.1200\/JCO.2010.32.6678"},{"key":"10.3238\/arztebl.m2023.0143_ref26","doi-asserted-by":"crossref","unstructured":"Kondagunta GV, Bacik J, Donadio A, et al.: Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23: 6549–55.","DOI":"10.1200\/JCO.2005.19.638"},{"key":"10.3238\/arztebl.m2023.0143_ref27","doi-asserted-by":"crossref","unstructured":"Oechsle K, Kollmannsberger C, Honecker F, et al.: Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and\/or multiply relapsed germ cell tumors. Eur Urol 2011; 60: 850–5.","DOI":"10.1016\/j.eururo.2011.06.019"},{"key":"10.3238\/arztebl.m2023.0143_ref28","doi-asserted-by":"crossref","unstructured":"Mackensen A, Haanen JBAG, Koenecke C, et al.: BNT211–01: a phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours. Ann Oncol 2022; 33: S808–69.","DOI":"10.1016\/j.annonc.2022.08.035"},{"key":"10.3238\/arztebl.m2023.0143_ref29","doi-asserted-by":"crossref","unstructured":"Kollmannsberger C, Tandstad T, Bedard PL, et al.: Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 2015; 33: 51–7.","DOI":"10.1200\/JCO.2014.56.2116"},{"key":"10.3238\/arztebl.m2023.0143_ref30","doi-asserted-by":"crossref","unstructured":"Ko JJ, Bernard B, Tran B, et al.: Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy. J Clin Oncol 2016; 34: 714–20.","DOI":"10.1200\/JCO.2015.64.7909"},{"key":"10.3238\/arztebl.m2023.0143_ref31","unstructured":"Joffe JK, Cafferty FH, Murphy L, et al.: Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: results from a randomized, phase III, noninferiority trial (TRISST). J Clin Oncol 2022; 40: 2468–78."},{"key":"10.3238\/arztebl.m2023.0143_ref32","doi-asserted-by":"crossref","unstructured":"Travis LB, Foss\u00e5 SD, Schonfeld SJ, et al.: Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97: 1354–65.","DOI":"10.1093\/jnci\/dji278"},{"key":"10.3238\/arztebl.m2023.0143_ref33","doi-asserted-by":"crossref","unstructured":"Hellesnes R, Myklebust TA, Fossa SD, et al.: Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort. J Clin Oncol 2021; 39: 3561–73.","DOI":"10.1200\/JCO.21.00637"},{"key":"10.3238\/arztebl.m2023.0143_ref34","doi-asserted-by":"crossref","unstructured":"de Haas EC, Altena R, Boezen HM, et al.: Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 2013; 24: 749–55.","DOI":"10.1093\/annonc\/mds527"},{"key":"10.3238\/arztebl.m2023.0143_ref35","doi-asserted-by":"crossref","unstructured":"Meinardi MT, Gietema JA, van der Graaf WTA, et al.: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725–32.","DOI":"10.1200\/JCO.2000.18.8.1725"},{"key":"10.3238\/arztebl.m2023.0143_ref36","doi-asserted-by":"crossref","unstructured":"Haugnes HS, Wethal T, Aass N, et al.: Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28: 4649–57.","DOI":"10.1200\/JCO.2010.29.9362"},{"key":"10.3238\/arztebl.m2023.0143_ref37","doi-asserted-by":"crossref","unstructured":"Lauritsen J, Hansen MK, Bandak M, et al.: Cardiovascular risk factors and disease after male germ cell cancer. J Clin Oncol 2020; 38: 584–92.","DOI":"10.1200\/JCO.19.01180"},{"key":"10.3238\/arztebl.m2023.0143_ref38","doi-asserted-by":"crossref","unstructured":"Oldenburg J: Hypogonadism and fertility issues following primary treatment for testicular cancer. Urol Oncol 2015; 33: 407–12.","DOI":"10.1016\/j.urolonc.2015.01.014"},{"key":"10.3238\/arztebl.m2023.0143_ref39","doi-asserted-by":"crossref","unstructured":"Travis LB, Fossa SD, Sesso HD, et al.: Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 2014; 106: dju044.","DOI":"10.1093\/jnci\/dju044"},{"key":"10.3238\/arztebl.m2023.0143_ref40","doi-asserted-by":"crossref","unstructured":"Frisina RD, Wheeler HE, Fossa SD, et al.: Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 2016; 34: 2712–20.","DOI":"10.1200\/JCO.2016.66.8822"},{"key":"10.3238\/arztebl.m2023.0143_ref41","doi-asserted-by":"crossref","unstructured":"Sprauten M, Haugnes HS, Bryd\u00f8y M, et al.: Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. Ann Oncol 2015; 26: 2133–40.","DOI":"10.1093\/annonc\/mdv328"},{"key":"10.3238\/arztebl.m2023.0143_ref42","unstructured":"ESMO: Patient guide on survivorship. ESMO.org. www.esmo.org\/for-patients\/patient-guides\/survivorship (last accessed on 14 April 2023)."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T09:09:08Z","timestamp":1701248948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":42,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2023.0143","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}